Építés alatt – nem éles oldal
Belépés
FelfüggesztveNo phase

Molecular Profiling Project

Megadott ok: Discussion under way on how to continue/restart the study in view of slow recruitment rate.

Key facts

Where
George Town, Kuala Lumpur és Petaling Jaya, MalajziaSee the 4 sites

Where in Malajzia

  • Penang Adventist HospitalGeorge Town, MalajziaNo longer taking part
  • Pantai Hospital Kuala LumpurKuala Lumpur, MalajziaNo longer taking part
  • University Malaya Medical Centre, Clinical Oncology DepartmentKuala Lumpur, MalajziaNo longer taking part
  • Beacon HospitalPetaling Jaya, MalajziaNo longer taking part

Trial details

Who runs it
National Cancer Centre, Singapore
Trial code
NCT04025515
Record updated
2026. május 12.
Original description
In this study, the investigators plan to undertake comprehensive molecular profiling of "actionable" alterations in lung cancer specimens in order to determine the prevalence of each genetic subtype in the local population.Read full original descriptionShow less

ATORG001 - Molecular Profiling Project

In this study, the investigators plan to undertake comprehensive molecular profiling of "actionable" alterations in lung cancer specimens in order to determine the prevalence of each genetic subtype in the local population.

Inclusion: The availability of sufficient archival tumor tissue specimen (15 slides of 4 microns per section); Age ≥ 21 years; WHO performance status ≤ 2; Life expectancy of ≥ 12 weeks; Patients should have adequate organ function for potential consideration into clinical trials (routine blood tests are valid within 14 days before enrollment):; Adequate bone marrow function as shown by: ANC ≥ 1.0 x 10\^9/L, Platelets ≥ 75 x 10\^9/L, Hb ≥ 7.5 g/dL; Alanine aminotransferase (ALT) and aspirate aminotransferase (AST) normal range (or ≤3.0 x ULN if liver metastases are present); Willing to provide signed informed consent; Patients whom do not fulfill the above criteria may be discussed on a case-by-case basis with the study team, for potential enrolment.

Exclusion: No more than 3 lines of cytotoxic chemotherapy at the time of enrolment.

ClinicalTrials.gov NCT04025515